Tocilizumab for COVID-19: a real ‘miracle drug’?

Sundus NasimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan; Correspondence[email protected]

Shariq Haider HashmiNYU Grossman School of Medicine, New York City, NY, USA

Dua AzimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan;

Sohail KumarDow Medical College, Dow University of Health Sciences, Karachi, Pakistan;

http://orcid.org/0000-0002-7947-4553

Jasia NasimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan;

"Tocilizumab for COVID-19: a real ‘miracle drug’?." Infectious Diseases, 52(9), pp. 681–682

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tocilizumab for COVID-19: a real ‘miracle drug’?

Information for

Open access

Opportunities

Help and information

Tocilizumab for COVID-19: a real ‘miracle drug’?

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature